RxDoctor Payments DataLook up a doctor →

Jose Martel, MD

Clinical Cardiac Electrophysiology · South Miami, FLNPI 1124053061

Payments from drug & device makers

$106,767in general payments, 2019–2025

Across 747 payments — averaging $142.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$55K
  • Medtronic$18K
  • Philips North America LLC$13K
  • Boehringer Ingelheim$10K
  • Boston Scientific$5K
  • Cardiva Medical, Inc.$3K
  • plus $3K from 27 others

What the payments were for

  • Consulting fees$54,72951%
  • Speaking & faculty fees$9,0008%
  • Travel & lodging$6,7696%
  • Food & beverage$36,25234%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$106,767 in reported general payments places this provider in the 75th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$509,855
Medicare patients
1,264
Services billed
6,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban220$203,467
XareltoRivaroxaban38$44,397
EntrestoSacubitril/Valsartan47$39,889
OzempicSemaglutide35$39,581
MultaqDronedarone Hcl17$23,348
FarxigaDapagliflozin Propanediol17$19,760
Praluent PenAlirocumab12$5,699
Dabigatran EtexilateDabigatran Etexilate Mesylate27$4,669
Flecainide Acetate145$3,616
Metoprolol Succinate150$1,905
Amiodarone Hcl100$1,073
Midodrine Hcl21$924
SotalolSotalol Hcl31$718
Labetalol Hcl17$576
Propranolol Hcl ErPropranolol Hcl11$539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$211$203,467220 claims
Johnson & JohnsonXarelto$184$44,39738 claims
NovartisEntresto$57$39,88947 claims
Novo NordiskOzempic$14$39,58135 claims
Sanofi-aventis U.S. LLCMultaq$35$23,34817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →